Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period.

1. Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 – Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
by
GBI Research
Explore all reports for
“Dermatology Therapeutics” market
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

2. Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 – Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
GBI Research has released its pharma report “ Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 Continued Uptake of Biologics and Novel Pipeline Drugs to
Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the
forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major
markets. This growth will be driven by a rising treatment population and the continued
uptake of biologics.
Biologics will continue to drive market growth despite leading brands Enbrel (etanercept),
Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the
major markets over the forecast period. Although the market will suffer revenue losses as
a result of sales erosion from biosimilar competitors, this will be offset by the emergence
of novel therapies. Most notably, these include monoclonal antibodies secukinumab,
ixekizumab and brodalumab, which are currently being developed by Alcon (Novartis
subsidiary), Eli Lilly and Amgen, respectively.
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

3. Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 – Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
Scope
•An introduction to psoriasis, which includes symptoms, epidemiology, etiology,
pathophysiology, diagnosis and treatment
•Analysis of the major systemic therapies in the current psoriasis marketed landscape
•Analysis of the pipeline for psoriasis, which includes a breakdown of pipeline molecules
by phase of development, molecule type, molecular target and novelty. Psoriasis clinical
trials are analyzed by size, duration and failure rates, and a comparative analysis of the
most promising systemic pipeline molecules is also provided.
•Forecast projections for the systemic psoriasis market to 2020. Analysis is provided for
the global market and each of the eight major markets. The forecast incorporates
projected, low and high variance scenarios based on treatment usage patterns and annual
therapy costs in each of the major markets.
•Analysis of strategic consolidations, including co-development and licensing deals, within
the psoriasis indication
Request a sample copy of this report @
http://www.rnrmarketresearch.com/contacts/request-sample?rname=148417 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

4. Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 – Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
Reasons to buy
•Understand the current systemic psoriasis marketed products landscape and recognize
the dominant therapeutic agents and pharmaceutical players involved
•Identify trends and developments within the psoriasis pipeline and consider how the
future competitive environment will be impacted
•Consider market opportunities and potential risks by examining the psoriasis clinical trial
landscape in relation to industry averages
•Observe projections for treatment usage patterns, annual therapy costs and market
growth in the eight major markets and understand reasons for variance in projected
patterns of growth in the eight major markets
Purchase a copy of this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=148417 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

5. Systemic Psoriasis Therapeutics in Major
Developed Markets to 2020 – Continued Uptake of
Biologics and Novel Pipeline Drugs to Drive Growth
Table of Contents
1 Table of Contents
1. List of Tables
2. List of Figures
2 Introduction
1. Overview
2. Epidemiology
3. Etiology, Co-morbidities and Risk Factors
4. Genetics
5. Psoriatic Arthritis
6. Mental Health Disorders
For other business research / market intelligence report on the ‘Dermatology
Therapeutics’ market, contact sales@rnrmarketresearch.com / Call +1 888 391
5441.
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441